Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

AG-221 (Enasidenib), IHD2 Inhibitor

AG-221 (Enasidenib), IHD2 Inhibitor

$129.00
A potent and selective inhibitor of IDH2 R140Q mutant.
Catalog No. Unit Price Qty
M60296-2s 2 mg solid $129.00

Details

Product Information
Molecular Weight: 473.38
Formula: C19H17F6N7O
Purity: ≥98%
CAS#: 1446502-11-9
Solubility: DMSO up to 50 mM
Chemical Name: 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

AG-221 (Enasidenib) is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 ~16 nM. It can reduce intracellular and extracellular levels of 2-HG in TF-1/IDH2 (R140Q) mutant cells in a dose-dependent manner. It can reduce IDH2 (R140Q)-induced GM-CSF-independent growth, reduce histone hypermethylation associated with elevated levels of 2-HG. In vivo treatment with AG-221 in U87MG IDH2 (R140Q) tumor xenograft model lead to a reduction in tumor 2-HG concentration. A dose dependent decrease in leukemia and evidence of normal differentiation was seen in AG-221 treated NOD/SCID mice engrafted with AMM7577-P2 cells. Now the drug is in clinical trials for IDH2 mutant-positive AML.

How to Use:

In vitro:
AG-221 was used at 1 µM in vitro and cellular assays.
In vivo:
AG-221 was dosed orally to mice bearing IDH2 mutant tumors at 5-50 mg/Kg once per day.


Reference:

  • 1. http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-publications
  • 2. Chong-Hui Gu, et al. Crystalline forms of therapeutically active compounds and use thereof. (2015) PCT WO 2015018060



AG-221_spec.pdf      
AG-221_MSDS.pdf      


Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 473.38
Formula: C19H17F6N7O
Purity: ≥98%
CAS#: 1446502-11-9
Solubility: DMSO up to 50 mM
Chemical Name: 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

AG-221 (Enasidenib) is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 ~16 nM. It can reduce intracellular and extracellular levels of 2-HG in TF-1/IDH2 (R140Q) mutant cells in a dose-dependent manner. It can reduce IDH2 (R140Q)-induced GM-CSF-independent growth, reduce histone hypermethylation associated with elevated levels of 2-HG. In vivo treatment with AG-221 in U87MG IDH2 (R140Q) tumor xenograft model lead to a reduction in tumor 2-HG concentration. A dose dependent decrease in leukemia and evidence of normal differentiation was seen in AG-221 treated NOD/SCID mice engrafted with AMM7577-P2 cells. Now the drug is in clinical trials for IDH2 mutant-positive AML.

How to Use:

In vitro:
AG-221 was used at 1 µM in vitro and cellular assays.
In vivo:
AG-221 was dosed orally to mice bearing IDH2 mutant tumors at 5-50 mg/Kg once per day.


Reference:

  • 1. http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-publications
  • 2. Chong-Hui Gu, et al. Crystalline forms of therapeutically active compounds and use thereof. (2015) PCT WO 2015018060



AG-221_spec.pdf      
AG-221_MSDS.pdf      


Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: